Rockefeller Capital Management L.P. Grows Stock Position in 10x Genomics, Inc. (NASDAQ:TXG)

Rockefeller Capital Management L.P. lifted its stake in 10x Genomics, Inc. (NASDAQ:TXG) by 37.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,504 shares of the company’s stock after buying an additional 4,746 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in 10x Genomics were worth $395,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. SG Americas Securities LLC lifted its holdings in 10x Genomics by 604.9% in the second quarter. SG Americas Securities LLC now owns 101,344 shares of the company’s stock valued at $1,971,000 after acquiring an additional 86,967 shares during the period. Lecap Asset Management Ltd. acquired a new position in shares of 10x Genomics in the 3rd quarter valued at $877,000. Marshall Wace LLP purchased a new stake in 10x Genomics during the second quarter worth $689,000. Benjamin F. Edwards & Company Inc. grew its position in 10x Genomics by 10,124.9% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 44,785 shares of the company’s stock valued at $871,000 after buying an additional 44,347 shares during the period. Finally, Deerfield Management Company L.P. Series C acquired a new stake in 10x Genomics during the second quarter valued at $11,612,000. Hedge funds and other institutional investors own 84.68% of the company’s stock.

10x Genomics Stock Performance

TXG opened at $16.15 on Wednesday. 10x Genomics, Inc. has a twelve month low of $12.95 and a twelve month high of $57.90. The firm has a market capitalization of $1.96 billion, a PE ratio of -10.52 and a beta of 1.84. The firm’s 50-day moving average price is $16.12 and its 200 day moving average price is $19.15.

10x Genomics (NASDAQ:TXG) last issued its earnings results on Tuesday, October 29th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.04. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The business had revenue of $151.65 million for the quarter, compared to analysts’ expectations of $158.84 million. During the same period in the previous year, the firm posted ($0.51) EPS. The business’s revenue for the quarter was down 1.3% compared to the same quarter last year. As a group, analysts predict that 10x Genomics, Inc. will post -1.4 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently commented on TXG. UBS Group dropped their target price on 10x Genomics from $25.00 to $20.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 30th. Citigroup dropped their price objective on 10x Genomics from $35.00 to $23.00 and set a “buy” rating on the stock in a report on Wednesday, October 30th. Barclays reduced their target price on 10x Genomics from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Leerink Partners assumed coverage on shares of 10x Genomics in a research note on Tuesday, September 3rd. They issued an “outperform” rating and a $35.00 price target on the stock. Finally, The Goldman Sachs Group cut their price target on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $29.19.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.